M9466 (Not yet branded)
Other Medications
Description
M9466 is a DNA damage response (DDR) pathway inhibitor being evaluated in combination with topoisomerase 1 inhibitors for advanced solid tumors, including colorectal cancer. This compound targets DNA repair mechanisms that cancer cells rely upon for survival when exposed to DNA-damaging chemotherapy agents. M9466 is designed to enhance the efficacy of topoisomerase 1 inhibitor-based regimens by preventing cancer cells from repairing chemotherapy-induced DNA damage.
Mechanism of Action
M9466 inhibits key proteins in the DNA damage response pathway, specifically targeting mechanisms that allow cancer cells to repair DNA breaks caused by topoisomerase 1 inhibitors like irinotecan. By blocking these repair pathways, M9466 enhances the cytotoxic effects of chemotherapy and promotes cancer cell death through accumulated DNA damage.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.